T1	Participants 120 142	small-cell lung cancer
T3	Participants 658 757	Among 235 eligible patients initially registered, 91 were randomized to receive maintenance therapy
T4	Participants 1497 1516	responding patients
T2	Participants 478 571	small-cell lung cancer (SCLC) patients who responded to six courses of induction chemotherapy
